Propulsid

There are currently no Propulsid cases before the Honorable Marina Corodemus. Propulsid was approved by the FDA in 1993 for the treatment of nocturnal heartburn. In March of 2000 the manufacturer of Propulsid, Janseen Phamaceutica, voluntarily removed the product from the market. Propulsid has been associated with ventricular tachycardia, ventricular fibrillation, torsades de pointes, and QT prolongation. From 1993 to 1998 there were approximately 38 deaths linked to the use of Propulsid.